MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells

Chia Jen Lee, Li Sung Hsu, Chia Herng Yue, Ho Lin, Yung Wei Chiu, Yu Yu Lin, Chih Yang Huang, Mien Chie Hung, Jer Yuh Liu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recent reports demonstrate that the expression of protein kinase C alpha (PKCα) in triple-negative breast cancer (TNBC) correlates with decreased survival outcomes. However, off-target effects of targeting PKCα and limited understanding of the signaling mechanisms upstream of PKCα have hampered previous efforts to manipulate this ubiquitous gene. This study shows that the expression of both myeloid zinc finger 1 (MZF-1) and Ets-like protein-1 (Elk-1) correlates with PKCα expression in TNBC. We found that the acidic domain of MZF-1 and the heparinbinding domain of Elk-1 facilitate the heterodimeric interaction between the two genes before the complex formation binds to the PKCα promoter. Blocking the formation of the heterodimer by transfection of MZF-160-72 or Elk-1145-157 peptide fragments at the MZF-1 / Elk-1 interface decreases DNA-binding activity of the MZF-1 / Elk-1 complex at the PKCα promoter. Subsequently, PKCα expression, migration, tumorigenicity, and the epithelial-mesenchymal transition potential of TNBC cells decrease. These subsequent effects are reversed by transfection with full-length PKCα, confirming that the MZF-1/Elk-1 heterodimer is a mediator of PKCα in TNBC cells. These data suggest that the next therapeutic strategy in treating PKCα-related cancer will be developed from blocking MZF-1/Elk-1 interaction through their binding domain.

Original languageEnglish (US)
Pages (from-to)59845-59859
Number of pages15
JournalOncotarget
Volume7
Issue number37
DOIs
StatePublished - 2016

Fingerprint

ets-Domain Protein Elk-1
Protein Interaction Domains and Motifs
Triple Negative Breast Neoplasms
Protein Kinase C-alpha
Zinc Fingers
Protein Kinase C
Therapeutics
Transfection
Peptide Fragments
Epithelial-Mesenchymal Transition
Genes

Keywords

  • Elk-1
  • MZF-1
  • PKCα
  • Triple-negative breast cancer cells

ASJC Scopus subject areas

  • Oncology

Cite this

Lee, C. J., Hsu, L. S., Yue, C. H., Lin, H., Chiu, Y. W., Lin, Y. Y., ... Liu, J. Y. (2016). MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells. Oncotarget, 7(37), 59845-59859. https://doi.org/10.18632/oncotarget.11337

MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells. / Lee, Chia Jen; Hsu, Li Sung; Yue, Chia Herng; Lin, Ho; Chiu, Yung Wei; Lin, Yu Yu; Huang, Chih Yang; Hung, Mien Chie; Liu, Jer Yuh.

In: Oncotarget, Vol. 7, No. 37, 2016, p. 59845-59859.

Research output: Contribution to journalArticle

Lee, CJ, Hsu, LS, Yue, CH, Lin, H, Chiu, YW, Lin, YY, Huang, CY, Hung, MC & Liu, JY 2016, 'MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells', Oncotarget, vol. 7, no. 37, pp. 59845-59859. https://doi.org/10.18632/oncotarget.11337
Lee, Chia Jen ; Hsu, Li Sung ; Yue, Chia Herng ; Lin, Ho ; Chiu, Yung Wei ; Lin, Yu Yu ; Huang, Chih Yang ; Hung, Mien Chie ; Liu, Jer Yuh. / MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells. In: Oncotarget. 2016 ; Vol. 7, No. 37. pp. 59845-59859.
@article{243e3888d8344833ac93a4396632e0e8,
title = "MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells",
abstract = "Recent reports demonstrate that the expression of protein kinase C alpha (PKCα) in triple-negative breast cancer (TNBC) correlates with decreased survival outcomes. However, off-target effects of targeting PKCα and limited understanding of the signaling mechanisms upstream of PKCα have hampered previous efforts to manipulate this ubiquitous gene. This study shows that the expression of both myeloid zinc finger 1 (MZF-1) and Ets-like protein-1 (Elk-1) correlates with PKCα expression in TNBC. We found that the acidic domain of MZF-1 and the heparinbinding domain of Elk-1 facilitate the heterodimeric interaction between the two genes before the complex formation binds to the PKCα promoter. Blocking the formation of the heterodimer by transfection of MZF-160-72 or Elk-1145-157 peptide fragments at the MZF-1 / Elk-1 interface decreases DNA-binding activity of the MZF-1 / Elk-1 complex at the PKCα promoter. Subsequently, PKCα expression, migration, tumorigenicity, and the epithelial-mesenchymal transition potential of TNBC cells decrease. These subsequent effects are reversed by transfection with full-length PKCα, confirming that the MZF-1/Elk-1 heterodimer is a mediator of PKCα in TNBC cells. These data suggest that the next therapeutic strategy in treating PKCα-related cancer will be developed from blocking MZF-1/Elk-1 interaction through their binding domain.",
keywords = "Elk-1, MZF-1, PKCα, Triple-negative breast cancer cells",
author = "Lee, {Chia Jen} and Hsu, {Li Sung} and Yue, {Chia Herng} and Ho Lin and Chiu, {Yung Wei} and Lin, {Yu Yu} and Huang, {Chih Yang} and Hung, {Mien Chie} and Liu, {Jer Yuh}",
year = "2016",
doi = "10.18632/oncotarget.11337",
language = "English (US)",
volume = "7",
pages = "59845--59859",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "37",

}

TY - JOUR

T1 - MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells

AU - Lee, Chia Jen

AU - Hsu, Li Sung

AU - Yue, Chia Herng

AU - Lin, Ho

AU - Chiu, Yung Wei

AU - Lin, Yu Yu

AU - Huang, Chih Yang

AU - Hung, Mien Chie

AU - Liu, Jer Yuh

PY - 2016

Y1 - 2016

N2 - Recent reports demonstrate that the expression of protein kinase C alpha (PKCα) in triple-negative breast cancer (TNBC) correlates with decreased survival outcomes. However, off-target effects of targeting PKCα and limited understanding of the signaling mechanisms upstream of PKCα have hampered previous efforts to manipulate this ubiquitous gene. This study shows that the expression of both myeloid zinc finger 1 (MZF-1) and Ets-like protein-1 (Elk-1) correlates with PKCα expression in TNBC. We found that the acidic domain of MZF-1 and the heparinbinding domain of Elk-1 facilitate the heterodimeric interaction between the two genes before the complex formation binds to the PKCα promoter. Blocking the formation of the heterodimer by transfection of MZF-160-72 or Elk-1145-157 peptide fragments at the MZF-1 / Elk-1 interface decreases DNA-binding activity of the MZF-1 / Elk-1 complex at the PKCα promoter. Subsequently, PKCα expression, migration, tumorigenicity, and the epithelial-mesenchymal transition potential of TNBC cells decrease. These subsequent effects are reversed by transfection with full-length PKCα, confirming that the MZF-1/Elk-1 heterodimer is a mediator of PKCα in TNBC cells. These data suggest that the next therapeutic strategy in treating PKCα-related cancer will be developed from blocking MZF-1/Elk-1 interaction through their binding domain.

AB - Recent reports demonstrate that the expression of protein kinase C alpha (PKCα) in triple-negative breast cancer (TNBC) correlates with decreased survival outcomes. However, off-target effects of targeting PKCα and limited understanding of the signaling mechanisms upstream of PKCα have hampered previous efforts to manipulate this ubiquitous gene. This study shows that the expression of both myeloid zinc finger 1 (MZF-1) and Ets-like protein-1 (Elk-1) correlates with PKCα expression in TNBC. We found that the acidic domain of MZF-1 and the heparinbinding domain of Elk-1 facilitate the heterodimeric interaction between the two genes before the complex formation binds to the PKCα promoter. Blocking the formation of the heterodimer by transfection of MZF-160-72 or Elk-1145-157 peptide fragments at the MZF-1 / Elk-1 interface decreases DNA-binding activity of the MZF-1 / Elk-1 complex at the PKCα promoter. Subsequently, PKCα expression, migration, tumorigenicity, and the epithelial-mesenchymal transition potential of TNBC cells decrease. These subsequent effects are reversed by transfection with full-length PKCα, confirming that the MZF-1/Elk-1 heterodimer is a mediator of PKCα in TNBC cells. These data suggest that the next therapeutic strategy in treating PKCα-related cancer will be developed from blocking MZF-1/Elk-1 interaction through their binding domain.

KW - Elk-1

KW - MZF-1

KW - PKCα

KW - Triple-negative breast cancer cells

UR - http://www.scopus.com/inward/record.url?scp=84991384835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991384835&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11337

DO - 10.18632/oncotarget.11337

M3 - Article

C2 - 27542222

AN - SCOPUS:84991384835

VL - 7

SP - 59845

EP - 59859

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -